Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics
Betsy Goodfellow | February 16, 2024 | News story | Research and Development | Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology
Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered into a research collaboration and license agreement for the development of novel immuno-oncology therapeutics.
Under the terms of this agreement, it is intended that the two companies will combine Kelonia’s iGPS with Xyphos’s ACCEL technology to develop novel in vivo CAR T-cell therapies, targeting a maximum of two programmes.
Xyphos is expected to be responsible for the development and commercialisation of the products created from this collaboration, while Kelonia will receive $40m upfront for the first programme and an additional $35m if Xyphos decides to exercise its options for the second programme. Kelonia will also be eligible for potential milestone and contingency payments up to a total of $800m.
Kevin Friedman PhD, chief executive officer and founder of Kelonia, commented: “Our iGPS platform has the potential to be a step change in the treatment of cancer. Combining Kelonia’s in vivo gene delivery capabilities with the ACCEL convertible CAR technology is an ideal marriage of technologies to create off-the-shelf, universal CAR T-cell therapies. We see revolutionary promise in this approach, and will work diligently with our partners at Astellas to unlock its full potential for patients that need it most.”
Adam Pearson, chief strategy officer at Astellas, “At Astellas, we have a strong commitment to developing novel treatments for patients with cancer and have positioned Immuno-Oncology as a Primary Focus of our R&D strategy. With iGPS, Kelonia has an elegant, cutting-edge in vivo delivery technology, and by combining with the ACCEL platform, we believe the collaboration will bring synergies between the two companies’ breakthrough research and will ultimately lead to expansion of Astellas’ portfolio and to delivery of innovative in vivo CAR T-cell therapies to cancer patients.”
Betsy Goodfellow
Related Content
AstraZeneca adds new heart failure target through collaboration with BenevolentAI
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery …
Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment
Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with …
Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib
US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have …
